Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

892.20GBp
23 Feb 2018
Change (% chg)

-5.80 (-0.65%)
Prev Close
898.00
Open
899.60
Day's High
903.80
Day's Low
873.20
Volume
409,052
Avg. Vol
982,733
52-wk High
2,346.00
52-wk Low
840.60

Select another date:

Tue, Feb 20 2018

UPDATE 1-Drugmaker Hikma names former Teva exec Olafsson as CEO; shares up

Feb 20 Hikma Pharmaceuticals Plc named former Teva Pharmaceutical executive Sigurdur Olafsson as its CEO, as the Jordan-based drugmaker looks to improve its struggling generics business.

BRIEF-Hikma Pharmaceutical Names Sigurdur Olafsson As CEO

* SAYS OLAFSSON WILL ALSO JOIN HIKMA'S BOARD OF DIRECTORS AS AN EXECUTIVE DIRECTOR

Drugmaker Hikma appoints Sigurdur Olafsson as CEO

Feb 20 Drugmaker Hikma Pharmaceuticals Plc said on Tuesday it appointed Sigurdur Olafsson as its chief executive, effective immediately.

Hikma wins right to market Roche drug copy in Middle East and North Africa

Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

Hikma wins right to market Roche drug copy in Middle East and North Africa

Dec 19 Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

BRIEF-Hikma Pharmaceuticals ‍Reaches Licensing Agreement With Celltrion

* ‍REACHES LICENSING AGREEMENT WITH CELLTRION FOR THIRD BIOSIMILAR PRODUCT IN MIDDLE EAST AND NORTH AFRICA​

BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos​

* ‍VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-Hikma Pharmaceuticals ‍invests in biosensor tech firm Biolinq​

* HIKMA PHARMACEUTICALS PLC - ‍INVESTED IN BIOLINQ IN COLLABORATION WITH M VENTURES WHICH LED $10 MILLION SERIES A ROUND OF FINANCING​ Source text for Eikon: Further company coverage:

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

UPDATE 1-Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Nov 9 Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

Select another date: